H.B. Fuller raised its full-year adjusted EBITDA guidance midpoint to a range of $650 million to $675 million while advancing its all-cash acquisition of Advanced Medical Solutions. The company reported second-quarter adjusted EBITDA of $181 million, up 9% year-over-year, and adjusted earnings per share of $1.41, a 19% increase. The offer for Advanced Medical Solutions is priced at 285 pence per share, implying a total enterprise value of approximately £715 million, and is expected to generate $55 million in run-rate synergies. Management also lifted the midpoint of its adjusted EPS guidance to $4.60 to $4.90 and expects third-quarter adjusted EBITDA between $180 million and $190 million. Pro forma net leverage at close is projected at about 4 times, with a plan to return to the 2.5 to 3 times target range within two years.
Advanced Medical Solutions Group plcH.B. Fuller's all-cash acquisition at 285 pence per share with expected synergies is positive for Advanced Medical Solutions shareholders.
H B Fuller CompanyRaised FY2026 adjusted EBITDA guidance midpoint and reported strong Q2 earnings with 9% EBITDA growth and 19% EPS growth.